EnteroBiotix secures £19M to support IBS microbiome clinical trial

Glasgow-based life sciences company EnteroBiotix has secured £19 million in funding to support the advancement of its microbiome-based therapies, including a large-scale clinical trial targeting irritable bowel syndrome (IBS). The round was led by Thairm Bio and the Scottish National Investment Bank, with participation from existing investors. The company has raised more than £65 million to date.